BioSpace News Archive

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Eli Lilly is betting on a new approach to axonal degeneration, announcing a definitive agreement to acquire Disarm Therapeutics, a privately-held biotech company committed to solving this mystery.

Altimmune, Inc., a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, announced that management will present at the following upcoming virtual investor conferences

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the first participant was enrolled in the observational PRECISION study, to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic.

Microbix Biosystems Inc., a life sciences innovator and exporter, announces its creation, external verification, and registration of new quality assessment products to help ensure the accuracy of workflows at labs conducting nucleic acid testing for sexually-transmitted Mycoplasma genitalium infections.

Theratechnologies Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced its financial results for the third quarter of fiscal year 2020 ended August 31, 2020.

Kraig Biocraft Laboratories, Inc., announces that it has completed production and genetic screening of its latest batch of spider silk silkworm eggs.

Ina Phase 1/2interventional study, preliminary open-label safety resultsin first six patientssupport advancementof APL-9, an investigational targeted C3 therapy, for severe COVID-19; additional 60-patient randomized, double-blind, controlled study cohort is currently enrolling

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board has ruled in favor of Precision BioSciences in two patent interference proceedings that challenged nine U.S. patents owned by Precision.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to support development of SZN-043, a novel liver-targeted regenerative antibody.